Citigroup’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

Citigroup’s Portfolio EPRS Stock Details EPRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-129	Closed	–	–	7457
2016 Q2	$0	Buy	129 +58	+82%	+$93	﹤0.01%	7963
2016 Q1	$0	Sell	71 -13	-15%	-$36	﹤0.01%	8269
2015 Q4	$0	Buy	+84	New	+$379	﹤0.01%	8342
2015 Q3	–	Sell	-160	Closed	-$1K	–	8357
2015 Q2	$1K	Buy	160 +155	+3,100%	+$1.06K	﹤0.01%	7478
2015 Q1	$0	Sell	5 -210	-98%	-$1.69K	﹤0.01%	7863
2014 Q4	$1K	Buy	+215	New	+$1.12K	﹤0.01%	7075

Other funds holding EPRS

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Citigroup's EPRS Position: Q3 2016 in Review

Citigroup sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q3 2016, closing a stake of 129 shares.

Citigroup first reported a position in EPRS in Q4 2014 and held it in 6 quarters. The position peaked at $1K in Q2 2015. 3 funds tracked by Wall St. Rank hold EPRS as of Q3 2016.

Citigroup reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q3 2016 after selling out during the quarter.
Citigroup sold 129 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q3 2016.
Citigroup first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q4 2014 and held it in 6 quarters.
Citigroup's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $1K in Q2 2015.
3 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q3 2016.

Based on Citigroup's 13F filing for Q3 2016, filed 10 Nov 2016.